Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Down 5.73%
As of Monday, October 05, Elicio Therapeutics, Inc.’s ELTX share price has dipped by 5.73%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Up 5.29%
As of Monday, September 21, Elicio Therapeutics, Inc.’s ELTX share price has surged by 5.29%, which has investors questioning if this is right time to sell.Michael Rose
Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Down 5.03%
As of Wednesday, September 16, Elicio Therapeutics, Inc.’s ELTX share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Down 5.20%
As of Friday, September 04, Elicio Therapeutics, Inc.’s ELTX share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Michael Rose
Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Up 5.94%
As of Tuesday, August 04, Elicio Therapeutics, Inc.’s ELTX share price has surged by 5.94%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ELTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $41.0 | $208.8 | 15% |
|
| Shares Out (Mil) | 19.2 | 53.9 | 30% |
|
| Institutional Ownership | 49.2% | 93.1% | 23% |
|
| Float (Mil) | 19.2 | 41.4 | 28% |
|
| Beta | 1.86 | 0.95 | 90% |
|
| Avg Daily Volume (000s) | 245 | 614 | 48% |
|
| Price Change (52-week) |
(85.3%) | 45.3% | 7% |
|
| Growth | ELTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (20.3%) | (10.2%) | 20% |
|
| EPS (5yr) | (12.0%) | 15.7% | 20 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.0%) | (15.7%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.430) | ($1.888) | ($1.690) | |
| Month Ago EPS | ($0.440) | ($1.950) | ($2.165) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.473) | ($2.068) | ($2.430) | |
| Year/Year Chg | 0.7% | (26.9%) | (53.6%) | |
| Financials | ELTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($38) | ($44) | 19% |
|
| EPS (TTM) | ($2.172) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($38) | ($33) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $40 | $174 | 15% |
|
| Valuation | ELTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.33 | 2.09 | 77% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ELTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (124.4%) | (47.2%) | 4% |
|
| ROE | (774.6%) | (54.2%) | 0% |
|
| Liabilities to Assets | 74.7% | 29.1% | 70% |
|
| F-Score | 4 | 2 | 33% |
|
Elicio Therapeutics, Inc. did not pass any screens on 10/16/2026.
